Group 1 - The Hong Kong innovative drug sector has seen significant growth, with ETFs such as the Hong Kong Innovative Drug ETF, Hang Seng Innovative Drug ETF, and Hong Kong Stock Connect Innovative Drug ETF rising over 70% year-to-date [1][3] - The sector demonstrated resilience, with a slight decline of less than 1% followed by a recovery, contrasting with broader market declines, as the Hang Seng Biotechnology Index surged by 4% [1] - The year-to-date performance of the top three ETFs in the innovative drug sector includes 71.59% for the Hong Kong Stock Connect Innovative Drug ETF, 71.27% for the Hang Seng Innovative Drug ETF, and 70.79% for the Hong Kong Innovative Drug ETF [1][3] Group 2 - The capital inflow into the Hong Kong Stock Connect Innovative Drug Index was notable, attracting 2.51 billion yuan, while other indices experienced significant outflows [7] - The report indicates that the innovative drug sector's growth is attributed to factors such as low valuations, policy support, and international business development [5][6] - The potential for the Hong Kong Stock Connect Innovative Drug ETF to double in value within a short timeframe is highlighted, assuming a daily growth rate of 3% [5][6]
疯了!年内首只翻倍基诞生?
Ge Long Hui·2025-06-12 09:16